Bristol-Myers Squibb Company's financial statements for the three and nine months ended September 30, 2022, show decreases in total revenues and net earnings compared to the same periods in 2021. The company's operating expenses cover various aspects such as costs of products sold, marketing, selling and administrative expenses, research and development expenses, and non-controlling interests. It also reports comprehensive income and cash flows, highlighting financial activities such as operating, investing, and financing activities. The notes in the statements discuss the basis of presentation, business segment information, use of estimates and judgments, reclassifications, and recently issued accounting standards. The revenue is further detailed by nature and region. Additionally, the text discusses the hedging strategies employed by the company, including cash flow hedges and fair value hedges using derivatives like interest rate swap contracts and foreign currency forward contracts. It also mentions the impact of these instruments on financial statements, their effectiveness in offsetting risks, and covers the company's debt obligations, credit facilities, receivables, inventories, property, plant, and equipment, as well as goodwill and other intangible assets. The actions related to debt, amortization, impairment charges, and acquisitions by the company are also outlined.
The text provides a comprehensive analysis of Bristol-Myers Squibb Company's financial condition and operations. It focuses on the company's development of innovative medicines for serious diseases, recent product approvals, and revenue growth by 1% in 2022 driven by new product approvals. There are external factors noted such as government actions on drug pricing, the impact of the COVID-19 pandemic, and revenue changes by region. The document also addresses specific financial details including revenue declines in the U.S. and internationally for certain products due to factors like generic competition and impacts on key drugs like Revlimid. The text highlights expenses such as costs of products sold, marketing, administrative costs, and R&D expenditures, as well as income taxes, non-GAAP financial measures, and specified items affecting tax rates. Additionally, details on significant product approvals, acquisitions, divestitures, and other developments within the company are elaborated upon.
Refer to "Item 7A" in the 2021 Form 10-K for a discussion on the company's market risk, including quantitative and qualitative disclosures.
The management of the company conducted an evaluation of the design and operation of its disclosure controls and procedures, as required by Exchange Act Rules, and concluded that they were effective as of September 30, 2022. Additionally, there were no significant changes in the company's internal control over financial reporting during the quarter that ended on September 30, 2022.
The text refers to how information regarding legal proceedings can be located in the financial statements under "Item 1. Financial Statements—Note 17. Legal Proceedings and Contingencies."
The text provided states that there have been no significant alterations in the risk factors disclosed in the company's 2021 Form 10-K.
The text provides a summary of the unregistered sales of equity securities and the use of proceeds during the three months ending September 30, 2022. It includes information about the total number of shares purchased, their average prices, shares repurchased as part of publicly announced programs, and remaining share repurchase authorization amounts. The text also discusses the Board of Directors' authorizations for share repurchases and the accelerated share repurchase agreements entered into by the company. It details the number of shares received by the company and transferred to treasury stock as part of the ASR, with an average repurchase price per share specified.
I'm here to help! Please go ahead and provide the text parts that you want me to summarize for you.
I am ready to receive and summarize the text parts you have provided. Please proceed with sharing the text for summarization.
I understand that you need a summary based on the text you are going to send in parts. Please go ahead and provide the text for summarization.
The text provides information about the exhibits included in the document, such as certification letters and various XBRL taxonomy extension documents. It also lists trademarked products and their respective owners, as well as a summary of abbreviated terms related to Bristol-Myers Squibb Company and its subsidiaries. The document includes a signature section where the report is signed by the Chairman of the Board and Chief Executive Officer, Giovanni Caforio, M.D., and the Chief Financial Officer, David V. Elkins, on behalf of Bristol-Myers Squibb Company.
